

A David Burden

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1147035/a-david-burden-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70
papers

4,247
citations

32
h-index

65
g-index

73
ext. papers

5,164
ext. citations

4.7
avg, IF

4.93
L-index

#	Paper	IF	Citations
70	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012 , 44, 1341-8	36.3	681
69	Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. <i>American Journal of Human Genetics</i> , 2011 , 89, 432-7	11	362
68	British Association of Dermatologists Guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009 , 161, 987-1019	4	356
67	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2632-2640	4.3	262
66	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , 2005 , 153, 486-97	4	199
65	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. <i>British Journal of Dermatology</i> , 2017 , 177, 628-636	4	158
64	Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2012 , 166, 179-88	4	147
63	European consensus statement on phenotypes of pustular psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1792-1799	4.6	122
62	Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. <i>New England Journal of Medicine</i> , 2019 , 380, 981-983	59.2	112
61	AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. <i>American Journal of Human Genetics</i> , 2014 , 94, 790-7	11	105
60	Gadodiamide contrast agent activates fibroblasts: a possible cause of nephrogenic systemic fibrosis. <i>Journal of Pathology</i> , 2008 , 214, 584-93	9.4	104
59	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1646-1654	4.3	91
58	Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. <i>British Journal of Dermatology</i> , 2001 , 145, 546-53	4	84
57	AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 2251-2259	4.3	84
56	The British Association of Dermatologists Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012 , 166, 545-54	4	81
55	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 1021-1026	11.5	80
54	IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 1067-1070.e9	11.5	73

53	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. <i>British Journal of Dermatology</i> , 2015 , 173, 510-8	4	67
52	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2120-2130	11.5	63
51	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. <i>British Journal of Dermatology</i> , 2006 , 154, 345-52	4	62
50	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2964-2970	4.3	58
49	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1584-1591	4.3	49
48	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018 , 154, 581-588	5.1	46
47	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). <i>British Journal of Dermatology</i> , 2020 , 182, 1158-1166	4	39
46	Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1344-1352	4.5	38
45	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019 , 180, 1069-1076	4	38
44	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017 , 176, 1297-1307	4	37
43	Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012 , 167 Suppl 3, 12-20	4	36
42	Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. <i>Brain, Behavior, and Immunity</i> , 2016 , 51, 29-38	16.6	35
41	Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. <i>British Journal of Dermatology</i> , 2007 , 156, 473-9	4	35
40	Psoriasis in children: a guide to its diagnosis and management. <i>Paediatric Drugs</i> , 2001 , 3, 673-80	4.2	34
39	Exposure to biological therapies during conception and pregnancy: a systematic review. <i>British Journal of Dermatology</i> , 2018 , 178, 95-102	4	32
38	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 115-123	4.3	32
37	Tinea nigra secondary to <i>Exophiala werneckii</i> responding to itraconazole. <i>British Journal of Dermatology</i> , 1997 , 137, 483-4	4	31
36	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012 , 166, 189-95	4	30

35	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 816-826.e3	4.3	27
34	Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. <i>British Journal of Dermatology</i> , 2020 , 183, 638-649	4	24
33	Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 85-94	4.3	19
32	Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 271-273	4.3	19
31	Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. <i>Dermatology and Therapy</i> , 2021 , 11, 571-585	4	18
30	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 769-778	4.6	18
29	Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. <i>BMJ Open</i> , 2021 , 11, e043666	3	17
28	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020 , 107, 539-543	11	16
27	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017 , 177, 828-836	4	15
26	MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2. <i>Journal of Biological Chemistry</i> , 2018 , 293, 3003-3012	5.4	15
25	Long-term patient satisfaction with cosmetic outcome of minor cutaneous surgery. <i>Australasian Journal of Dermatology</i> , 2001 , 42, 102-5	1.3	15
24	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019 , 155, 1235-1243	5.1	14
23	Identifying a gene for psoriasis on chromosome 6 (Psors1). <i>British Journal of Dermatology</i> , 2000 , 143, 238-41	4	12
22	Secukinumab for patients failing previous tumour necrosis factor- α inhibitor therapy: results of a randomized open-label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020 , 183, 60-70	4	11
21	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018 , 19, 465	2.8	11
20	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019 , 181, 1265-1274	4	10
19	The spectrum of nail involvement in palmoplantar pustulosis. <i>British Journal of Dermatology</i> , 1996 , 134, 1079-1082	4	10
18	Human Trichophyton equinum infection treated with terbinafine. <i>Clinical and Experimental Dermatology</i> , 1994 , 19, 359-60	1.8	8

17	Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2644-2646	4.3	7
16	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019 , 180, 894-901	4	6
15	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). <i>British Journal of Dermatology</i> , 2021 ,	4	6
14	A randomized, placebo-controlled trial of oral itraconazole in scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2000 , 11, 85-89	2.8	5
13	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020 , 156, 1216-1222	5.1	5
12	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2129-2137	4.3	4
11	Psoriasis. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2013 , 43, 334-8; quiz 339	0.9	4
10	Absent lentiginos in psoriatic plaques. <i>British Journal of Dermatology</i> , 2002 , 147, 1044-5	4	3
9	Etanercept or infliximab for psoriasis? An independent randomized clinical trial. <i>British Journal of Dermatology</i> , 2017 , 176, 565	4	2
8	Clinical Disease Measures in Generalized Pustular Psoriasis.. <i>American Journal of Clinical Dermatology</i> , 2022 , 23, 39	7.1	1
7	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e498-e501	4.6	1
6	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e496-e498	4.6	1
5	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. <i>BMC Rheumatology</i> , 2021 , 5, 19	2.9	1
4	Psoriasis, COVID-19 and shielding. <i>British Journal of Dermatology</i> , 2021 , 185, 7-8	4	0
3	How do you determine the optimal biologic treatment for psoriasis?. <i>British Journal of Dermatology</i> , 2019 , 181, 247-248	4	
2	What is the optimal topical treatment for limited plaque psoriasis?. <i>British Journal of Dermatology</i> , 2013 , 168, 925-6	4	
1	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022 , 9, 1-106	1.7	